ALK and cancer: Mutations in the epidermal growth factor receptor (EGFR), KRAS, Fibroblast growth factor receptor 1 (FGFR1), Anaplastic lymphoma kinase (ALK), MET, PIK3CABRAF, ROS1, NTRK, RET, HER2, LKB1, and TP53 [4–7] have been used as biomarkers to guide targeted cancer treatment.